American College of Cardiology Mar 31 2025 A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the rate of stroke, according to a randomized trial presented at the American College of Cardiology's Annual Scientific Session (ACC.25). The BHF PROTECT-TAVI trial is the largest randomized trial assessing the use of a cerebral embolic protection device during